Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 pharmacokinetic comparison of CAL-101 capsule and tablet formulations in healthy men
NL-OMON35094Phase 1Active, not recruiting
- Sponsor
- Calistoga Pharmaceuticals
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of idelalisib in leukemia and lymphoma (3 arms), sponsored by Calistoga Pharmaceuticals. Primary endpoints: Pharmacokinetics and Safety. Started Mar 2010; status: active, not recruiting.
02
Drugs
idelalisib
03
Conditions
leukemialymphoma
Beyond the preview
Go deeper on NL-OMON35094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35094.